FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311753783> ?p ?o ?g. }

• W4311753783 abstract "Abstract Background Deleterious outcomes associated with IET are well documented among hospitalized patients with infections. However, scant data exist on the consequences of IET among adult OPs with cUTIs. This study evaluated the association between receipt of IET and 30-day ED/IP visits among adult OPs with cUTIs. Methods Retrospective cohort study among Kaiser Permanente Southern California members from 2017-20. Inclusion criteria were age ≥18 years; cUTI diagnosis during an OP visit; positive urine culture with antibiotic (AB) susceptibility results; receipt of AB ±3 days of index urine culture; and not hospitalized on day of OP visit. For OPs with multiple cUTIs, only the index cUTI was considered. IET was defined as failure to receive an AB with in vitro microbiologic activity against all recovered cUTI pathogens ±3 days of culture collection date. Outcomes included all-cause and cUTI-related ED/IP visits ≥3 days to ≤30 days from index culture date. Logistic regression was used to adjust for baseline differences between appropriateness groups. Results During study period, 25,980 OPs with cUTIs met study criteria. Mean age was 60 years, majority female (57%), and E. coli (66%) was the most common pathogen. IET was noted in 2656 (10%) of patients. Comparison of baseline characteristics between appropriateness groups is shown in Table. Comparison of 30-day all-cause and cUTI-related ED/IP visits between IET and appropriate empiric therapy (AET) is shown in Figure. In the logistic regression, receipt of IET was associated with an increase odds of 30-day all-cause ED/IP visits (adjusted odds ratio (aOR)= 1.3; 95% CI: 1.2-1.4) and 30-day cUTI-related ED/IP visits (aOR=1.5; 95% CI: 1.4-1.7), respectively. Figure Conclusion Thirty-day all-cause and cUTI-related ED/IP visits were significantly higher among adult OPs with cUTI who received IET. As culture and susceptibility results are frequently unknown at the time of empiric therapy selection, the findings highlight the critical need to use institution-specific antibiotic resistance risk stratification tools, in tandem with rapid diagnostic tests, to guide empiric antibiotic decisions among OPs with cUTIs as measures to ensure patients receive AET and maximize chances of a successful clinical outcome. Disclosures Thomas P. Lodise, PharmD, PhD, Spero Therapeutics: Advisor/Consultant Lie Hong H. Chen, DrPH, MSPH, Spero Therapeutics: Grant/Research Support Katia J. Bruxvoort, PhD, MPH, Dynavax: Grant/Research Support|Gilead: Grant/Research Support|Glaxosmithkline: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|Seqirus: Grant/Research Support Rong Wei, MA, Spero Therapeutics: Grant/Research Support|Spero Therapeutics: Grant/Research Support Theresa M. Im, MPH, Spero Therapeutics: Grant/Research Support Richard Contreras, MS, Spero Therapeutics: Grant/Research Support Mauricio Rodriguez, PharmD, MS-HEOR, BCPS, BCCCP, BCIDP, Spero Therapeutics: Employee Larry Friedrich, PharmD, Spero Therapeutics: Employee Jennifer Reese, PharmD, Spero Therapeutics: Employee Sara Y. Tartof, PhD MPH, Pfizer: Grant/Research Support|Spero: Grant/Research Support." @default.
• W4311753783 created "2022-12-28" @default.
• W4311753783 creator A5018906764 @default.
• W4311753783 creator A5025702241 @default.
• W4311753783 creator A5036077150 @default.
• W4311753783 creator A5036366931 @default.
• W4311753783 creator A5053797926 @default.
• W4311753783 creator A5057658848 @default.
• W4311753783 creator A5071575342 @default.
• W4311753783 creator A5073430426 @default.
• W4311753783 creator A5084249121 @default.
• W4311753783 creator A5086404703 @default.
• W4311753783 date "2022-12-01" @default.
• W4311753783 modified "2023-09-26" @default.
• W4311753783 title "2232. Association between Inappropriate Empiric Therapy (IET) and 30-Day Emergency Department/Inpatient (ED/IP) Visits Among Adult Outpatients (OPs) with Complicated Urinary Tract Infections (cUTIs)" @default.
• W4311753783 doi "https://doi.org/10.1093/ofid/ofac492.1850" @default.
• W4311753783 hasPublicationYear "2022" @default.
• W4311753783 type Work @default.
• W4311753783 citedByCount "0" @default.
• W4311753783 crossrefType "journal-article" @default.
• W4311753783 hasAuthorship W4311753783A5018906764 @default.
• W4311753783 hasAuthorship W4311753783A5025702241 @default.
• W4311753783 hasAuthorship W4311753783A5036077150 @default.
• W4311753783 hasAuthorship W4311753783A5036366931 @default.
• W4311753783 hasAuthorship W4311753783A5053797926 @default.
• W4311753783 hasAuthorship W4311753783A5057658848 @default.
• W4311753783 hasAuthorship W4311753783A5071575342 @default.
• W4311753783 hasAuthorship W4311753783A5073430426 @default.
• W4311753783 hasAuthorship W4311753783A5084249121 @default.
• W4311753783 hasAuthorship W4311753783A5086404703 @default.
• W4311753783 hasConcept C118552586 @default.
• W4311753783 hasConcept C126322002 @default.
• W4311753783 hasConcept C142724271 @default.
• W4311753783 hasConcept C151956035 @default.
• W4311753783 hasConcept C156957248 @default.
• W4311753783 hasConcept C167135981 @default.
• W4311753783 hasConcept C187212893 @default.
• W4311753783 hasConcept C204787440 @default.
• W4311753783 hasConcept C2779181126 @default.
• W4311753783 hasConcept C2780724011 @default.
• W4311753783 hasConcept C71924100 @default.
• W4311753783 hasConcept C77411442 @default.
• W4311753783 hasConceptScore W4311753783C118552586 @default.
• W4311753783 hasConceptScore W4311753783C126322002 @default.
• W4311753783 hasConceptScore W4311753783C142724271 @default.
• W4311753783 hasConceptScore W4311753783C151956035 @default.
• W4311753783 hasConceptScore W4311753783C156957248 @default.
• W4311753783 hasConceptScore W4311753783C167135981 @default.
• W4311753783 hasConceptScore W4311753783C187212893 @default.
• W4311753783 hasConceptScore W4311753783C204787440 @default.
• W4311753783 hasConceptScore W4311753783C2779181126 @default.
• W4311753783 hasConceptScore W4311753783C2780724011 @default.
• W4311753783 hasConceptScore W4311753783C71924100 @default.
• W4311753783 hasConceptScore W4311753783C77411442 @default.
• W4311753783 hasIssue "Supplement_2" @default.
• W4311753783 hasLocation W43117537831 @default.
• W4311753783 hasOpenAccess W4311753783 @default.
• W4311753783 hasPrimaryLocation W43117537831 @default.
• W4311753783 hasRelatedWork W2026095104 @default.
• W4311753783 hasRelatedWork W2433229788 @default.
• W4311753783 hasRelatedWork W2980093723 @default.
• W4311753783 hasRelatedWork W3005450714 @default.
• W4311753783 hasRelatedWork W3083654737 @default.
• W4311753783 hasRelatedWork W3152215807 @default.
• W4311753783 hasRelatedWork W4205775747 @default.
• W4311753783 hasRelatedWork W4220662621 @default.
• W4311753783 hasRelatedWork W4232888950 @default.
• W4311753783 hasRelatedWork W4238308949 @default.
• W4311753783 hasVolume "9" @default.
• W4311753783 isParatext "false" @default.
• W4311753783 isRetracted "false" @default.
• W4311753783 workType "article" @default.